Target intelligence / Profile preview

Laminin receptor 1 (LAMR1) (LAMR1)

Target
LAMR1
Molecular classification
Receptor, Ribosomal protein, Cell adhesion molecule
01

Overview

Laminin receptor 1 (LAMR1), also known as the 37/67-kDa laminin receptor or Ribosomal Protein SA (RPSA), is a multifunctional protein that serves as a primary cell-surface receptor for Adeno-associated virus serotype 8 (AAV8) (Akache et al., 2006). While it functions intracellularly as a component of the 40S ribosomal subunit, its expression on the plasma membrane of hepatocytes is a critical determinant of the high liver tropism and transduction efficiency exhibited by AAV8-based gene therapies (UniProt P08865). AAV8 capsids bind to the extracellular domain of LAMR1 to facilitate viral attachment and subsequent internalization via receptor-mediated endocytosis (Zincarelli et al., 2008). In addition to LAMR1, the universal Adeno-associated virus receptor (AAVR, also known as KIAA0319L) is required for the post-attachment trafficking of AAV8 within the cell (Pillay et al., 2016). LAMR1's involvement in cell-matrix adhesion and its frequent overexpression in various cancers make it a significant factor in both viral vector design and oncology (Nelson et al., 2008). Understanding the interaction between AAV8 and LAMR1 is essential for optimizing liver-directed gene transfer and managing the safety profile of therapies for conditions like hemophilia and metabolic disorders (Wang et al., 2010).

Other names
37/67-kDa laminin receptorRibosomal protein SARPSALaminin-binding proteinLBPNEM/1CHD467LR37LRP
02

Mechanism of action

Mediates viral attachment to the hepatocyte surface and facilitates cellular entry via receptor-mediated endocytosis

03

Biological functions

Viral entryCell-matrix adhesionProtein translationRibosome assemblySignal transduction
04

Disease associations

Infection (AAV entry)Cancer (metastasis and progression)Neurodegenerative disease (prion protein binding)Hemophilia A (therapeutic target)Hemophilia B (therapeutic target)Ornithine transcarbamylase deficiency (therapeutic target)
05

Safety considerations

Capsid-mediated immunogenicityHepatotoxicity (elevated liver enzymes)Pre-existing neutralizing antibodies limiting efficacyOff-target transduction of non-hepatic tissues
06

Interacting drugs

Dirloctocogene iteparvovec (SPK-8011)

4 more in the full profile.

07

Biomarkers

LAMR1 protein expression levelsAnti-AAV8 neutralizing antibody (NAb) titersLiver transaminases (ALT/AST) for monitoring hepatotoxicity

Beyond the preview

Go deeper on Laminin receptor 1 (LAMR1) (LAMR1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Laminin receptor 1 (LAMR1) (LAMR1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call